VD-CAG AML Treatment: 11-Gene Prognostic Signature from Multi-Omics Profiling

A study by Jirui Tang, last updated in May 2026, integrates RNA sequencing and proteomics data from 15 non-M3 acute myeloid leukemia patients treated with the VD-CAG regimen. The dataset contains the resulting robust 11-gene prognostic signature, validated using external cohorts TCGA-LAML and Beat AML.

Use Cases

• Validate the 11-gene signature (TLN1, ARL15, etc.) for patient risk stratification based on overall survival.
• Analyze molecular alterations in MAPK signaling and cell adhesion pathways associated with VD-CAG treatment response.
• Investigate the correlation between gene modules identified by WGCNA and composite complete remission.
• Compare transcriptomic and proteomic changes, such as FNDC3B downregulation, pre- and post-treatment.

Strengths

• Prognostic signature validated in two independent cohorts (TCGA: HR=3.60, p=7.6e-10; Beat AML: HR=1.89, p=1.3e-3).
• Integrative multi-omics profiling includes RNA-seq from 10 patient pairs and DIA proteomics from 5 patient pairs.
• Signature performance reported with 3-year AUC metrics (0.79 in discovery, 0.83 in validation).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (150.3 KB), indicating limited primary data scope.

Provenance

Source

figshare, author Jirui Tang.

Collection Method

RNA sequencing and data-independent acquisition (DIA) proteomics on bone marrow samples from 15 non-M3 AML patients receiving VD-CAG induction therapy.

Time Range

null

Freshness

Last updated 2026-05-19 04:22:46; freshness should be verified.

Geography

null